Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057967 · ClinicalTrials.gov registry record · Phase 2
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00057967 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 37 participants.
The verdict
NCT00057967, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with relapsed or refractory advanced mycosis fungoides or Sézary syndrome.
Interventions
- BIOLOGICAL alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2000-07 |
| Est. Completion | 2010-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057967
The ClinicalTrials.gov registry entry for NCT00057967 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alemtuzumab is the first listed.
NCT00057967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057967 about?
NCT00057967 is a clinical study titled "Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome". RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with relapsed or refractory advanced my...
What is the current status of trial NCT00057967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2000-07. Estimated completion is 2010-07-26.
What interventions are being tested in trial NCT00057967?
The interventions under investigation include: alemtuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00057967?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.